Our work centers on the microbiota-cancer axis, advancing science-driven prebiotic care and next-generation therapeutic tools and medical devices. Button links to R&D page
Learn More
Our team is pioneering urogenital healthcare with first-in-class, patent-pending therapeutics and innovations in prebiotic personal care. Button to About Us
Learn MoreGlyciome is developing therapeutic drugs, medical devices, and personal care products that are changing genital care paradigms. Our products support healthy surface function across all ages. Common genital infections more than double the risk of developing genital cancers. Our patent portfolio combines cutting-edge science in metabolomics, nanotechnology, and human-centered design-thinking, to meet the demands of the $126B/yr. global personal and genital healthcare market.
Glyciome, LLC is a women-owned, Spokane-based, bioscience start-up commercializing first-in-class urogenital healthcare products. Our patent-pending therapeutics treat common genital infections and inflammation that contribute to genital cancers (such as those of the cervix, uterus, ovaries, prostate and penis). The formation and progression of these cancers are facilitated through a “microbiota-cancer axis” (i.e., the oncobiome), where harmful bacteria -and co-infections with viruses (such as herpes or HPV) - drive cancer-promoting genes and cell changes. Our founders have a unique understanding of genital ecosystem physiology which fosters development of breakthrough interventions with unparalleled efficacy and safety.
